Ductal carcinoma in situ - update on risk assessment and management.
Ductal carcinoma in situ (DCIS) accounts for ~20-25% of breast cancers. While DCIS is not life-threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over- or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS, discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.
['Pang|Jia-Min B|JM|', 'Gorringe|Kylie L|KL|', 'Fox|Stephen B|SB|']
D001943:Breast Neoplasms D002285:Carcinoma, Intraductal, Noninfiltrating D019468:Disease Management D018450:Disease Progression D005260:Female D006801:Humans D018570:Risk Assessment
breast neoplasms clinical markers clinical pathology patient care management